Wittbrodt E, Parker ED, McPheeters J. Health care utilization and costs in patients with type 2 diabetes treated with dapagliflozin or sitagliptin. Paper presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting; 2018 Apr 23-26; Boston, MA.

Toth P, Granowitz C, Hull M, Philip S. Diabetes mellitus and high triglycerides are significant predictors of major cardiovascular events and increased health care costs and resource utilization-a real-world analysis of high-risk statin-treated patients. Paper presented at: American Diabetes Association 78th Scientific Sessions; 2018 Jun 22-26; Orlando, FL.

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides (≥150 mg/dl) and diabetes mellitus are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. Paper presented at: 2018 AACE Annual Scientific & Clinical Congress; 2018 May 16-20; Boston, MA.


Canovatchel W, Thayer S, Chow W, Qiu R, Davies MJ. Efficacy of canagliflozin (CANA) versus dipeptidyl peptidase-4 inhibitors (DPP-4) in patients with type 2 diabetes mellitus (T2DM): Results from randomized controlled trials (RCTs) and a real-world (RW) study. Poster presented at: American Diabetes Association 76th Scientific Sessions; 2016 Jun 10-14; New Orleans, LA.


Thayer S, Williams S, Fan Y, Parasuraman S. Pre-index clinical differences between type 2 diabetes patients with renal impairment prescribed saxagliptin and other non-insulin anti-diabetic medications. Poster presented at: The Endocrine Society’s 94th Annual Meeting and Expo; 2012 Jun 23-26; Houston, TX.


Thayer S, Wei W, Brekke L, Buysman E, Hu W, Cuddihy R. How different were they? a retrospective study of real-world US Patients with type 2 diabetes mellitus (T2DM) initiating once-daily injectable pen therapy with insulin glargine or liraglutide. Poster presented at: 94th Annual Meeting of the Endocrine Society; 2012 Jun 23-26; Houston, TX.


